A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension
← catalyst calendarNCT07758634 · readout in 681 d
Sponsored by CRISPR Therapeutics AG (industry) · CRSP — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
69estimated
Sites
2
Countries
Australia, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-08 | estimated | When the study began enrolling |
| Primary completion | 2028-07-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-07-01 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hypertension
Interventions
- Drug: CTX340
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPhase 1: Incidence of dose-limiting toxicities (DLTs)
measured Up to 12 months
Phase 2: Percentage change in circulating angiotensinogen (AGT) concentration from baseline
measured Through 6 months of follow-up.
Permalink · CRSP's whole pipeline · Catalyst calendar · Every registered study · What changed